Pennsylvania HB1439 amends the Controlled Substance, Drug, Device and Cosmetic Act to schedule crystalline polymorph psilocybin in alignment with.

Pennsylvania HB1439 amends the Controlled Substance, Drug, Device and Cosmetic Act to ensure that the pharmaceutical composition of crystalline polymorph psilocybin is scheduled in accordance with federal law immediately upon approval by the United States Food and Drug Administration. This scheduling will align with federal regulations, including those under 21 U.S.C. The rescheduling will be published in the Pennsylvania Bulletin and will take effect thirty days after publication.

Pennsylvania HB1439 amends the Controlled Substance, Drug, Device and Cosmetic Act to schedule crystalline polymorph psilocybin in alignment with.

Pennsylvania HB1439 amends the Controlled Substance, Drug, Device and Cosmetic Act to ensure that the pharmaceutical composition of crystalline polymorph psilocybin is scheduled in accordance with federal law immediately upon approval by the United States Food and Drug Administration. This scheduling will align with federal regulations, including those under 21 U.S.C. The rescheduling will be published in the Pennsylvania Bulletin and will take effect thirty days after publication.